Establishment of Dividend Reinvestment Plan
Filed with ASX · · 32 pages · English
Australian Clinical Labs Limited (ASX: ACL) (ACL or Company) advises that it has established a Dividend Reinvestment Plan (DRP). The DRP provides eligible ACL shareholders with a convenient method of reinvesting all or part of their dividends in additional ACL shares. In accordance with ASX Listing Rule 3.10.8, a copy of the terms of the DRP are attached. A copy of the terms of the DRP are also av
Australian Clinical Labs Ltd on 6ix
In the deck
Earlier from Australian Clinical Labs
- Media Release - 1H22 Financial Results
- 1H22 Investor Presentation
- Appendix 4D
- Letter from Crescent Capital Partners
- Upgrade to 1H FY22 Pro Forma Expectations
Later from Australian Clinical Labs
- S&P DJI Announces March 2022 Quarterly Rebalance
- Response to Market Enquiries
- FY22 Investor Presentation
- Appendix 4E - Preliminary Financial Report
- Letter received from Crescent Capital
Follow Australian Clinical Labs into a list and get an email when it puts out news.
Follow Australian Clinical Labs